IGF1 and neoplasm: These candidate biomarkers can include all members of the complex IGF system (both systemic and local/tumor expression levels) and markers connected to the IGF system, including the downstream signaling pathways and gene signatures indicative of increased tumor insulin/IGF-I activity.